Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRIT Capital Partners Regulatory News (RCP)

Share Price Information for RIT Capital Partners (RCP)

Share Price is delayed by 15 minutes
Get Live Data
2,305.00    -15.00 (-0.65%)
Bid:
2,300.00
Ask:
2,305.00
Spread: 5.00 (0.217%)
Market Cap: £3.13b
RCP Live PriceLast checked at - London Stock Exchange

Intraday RIT Capital Partners Share Chart

Net Asset Value(s)

17 Feb 2026 07:00

RNS Number : 2279T
RIT Capital Partners PLC
17 February 2026
 

RIT Capital Partners PLC (LEI: P31Q1NLTW35JJGHA4667)

17 February 2026

January 2026 Net Asset Value (NAV)

RIT Capital Partners plc's ("RITs") unaudited diluted NAV as at 31 January 2026 (with debt at fair value) was 2,958p per £1 ordinary share (31 December 2025: 2,921p1), +1.3% for the month.

Global equities rose in January, supported by improving economic growth and emerging markets led gains. In the United States, resilient economic indicators broadened a public equities rally, with SMID-caps outperforming and market leadership rotating toward cyclical and defensive sectors. European and Asian equities also advanced.

In currency markets, the US dollar weakened, supporting risk appetite outside the United States. Commodity prices surged, led by energy, while positive momentum in precious metals was supported by dollar weakness and ongoing macroeconomic uncertainty.

Against this market backdrop, our portfolio delivered a solid performance during the month, led by Quoted Equities and Uncorrelated Strategies. 

Performance highlights

·

Quoted Equities contributed positively to NAV, led by strong performance from our emerging markets and commodities-related holdings.

·

Performance from Private Investments was flat in January while we await Q4 2025 valuations from our fund partners. As at 31 January, over 99% of the funds portfolio is held at 30 September 2025 reported valuations, with the remaining balance at 30 June 2025.

·

Uncorrelated Strategies, which acts as a steady diversifier of returns, contributed positively, led by gold and credit.

·

Currencies detracted from our NAV, primarily due to strengthening of sterling against the US dollar, leading to a negative translation effect for our global portfolio.

·

We continued our ongoing share buyback programme, repurchasing £6.9 million or approximately 309,000 shares in January, adding an estimated +5bps accretion to NAV.

 

1 As is customary at this point in our year-end process, the preliminary December NAV and associated performance numbers for 2025 are estimates, and subject to potential adjustment and audit. Changes made to the December 2025 NAV could impact January's opening NAV and therefore January's performance. The 2025 Annual Report and Accounts are expected to be finalised and published by early March.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVQQLFFQLLZBBL
Date   Source Headline
12th Aug 20227:00 amRNSNet Asset Value(s)
11th Aug 20229:45 amRNSBoard Appointments
2nd Aug 20227:00 amRNSHalf-year Report
20th Jul 20227:00 amRNSNet Asset Value(s)
21st Jun 20227:00 amRNSTransaction in Own Shares
20th Jun 20227:00 amRNSTransaction in Own Shares
16th Jun 20227:00 amRNSNet Asset Value(s)
17th May 20227:00 amRNSNet Asset Value(s)
4th May 20224:51 pmRNSResult of AGM
27th Apr 20222:24 pmRNSDirector/PDMR Shareholding
26th Apr 20224:40 pmRNSBoard Appointment
19th Apr 20227:00 amRNSNet Asset Value(s)
14th Mar 20227:00 amRNSNet Asset Value(s)
1st Mar 20227:00 amRNSAnnual Financial Report
23rd Feb 20224:18 pmRNSHolding(s) in Company
22nd Feb 20222:45 pmRNSHolding(s) in Company
17th Feb 20227:00 amRNSNet Asset Value(s)
15th Feb 20224:26 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSNet Asset Value(s)
15th Dec 20217:00 amRNSNet Asset Value(s)
3rd Dec 20217:00 amRNSDirector Declaration
23rd Nov 20215:22 pmRNSDirector/PDMR Shareholding
15th Nov 20217:00 amRNSNet Asset Value(s)
4th Nov 20214:57 pmRNSBoard Announcements
15th Oct 20217:00 amRNSNet Asset Value(s)
15th Sep 20217:00 amRNSNet Asset Value(s)
16th Aug 20217:00 amRNSNet Asset Value(s)
2nd Aug 20217:00 amRNSHalf-year Report
20th Jul 20217:00 amRNSNet Asset Value(s)
28th Jun 20216:17 pmRNSDirector/PDMR Shareholding
28th Jun 20217:00 amRNSTransaction in Own Shares
22nd Jun 20217:00 amRNSTransaction in Own Shares
15th Jun 20217:00 amRNSNet Asset Value(s)
21st May 20215:15 pmRNSDirector/PDMR Shareholding
18th May 20217:00 amRNSNet Asset Value(s)
22nd Apr 20215:52 pmRNSResult of AGM
19th Apr 20217:00 amRNSNet Asset Value(s)
13th Apr 20214:17 pmRNSHolding(s) in Company
1st Apr 20217:00 amRNSDirector/PDMR Shareholding
24th Mar 20216:17 pmRNSDirector/PDMR Shareholding
16th Mar 20217:00 amRNSTransaction in Own Shares
12th Mar 20217:00 amRNSNet Asset Value(s)
11th Mar 20217:00 amRNSHolding(s) in Company
5th Mar 20219:38 amRNSDirector/PDMR Shareholding
2nd Mar 20217:00 amRNSAnnual Financial Report
26th Feb 20218:10 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSHolding(s) in Company
15th Feb 20217:00 amRNSNet Asset Value(s)
4th Feb 20217:00 amRNSNet Asset Value(s)
23rd Dec 20207:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.